Larimar Therapeutics Inc

This advisory say-on-pay proposal asks shareholders to approve, on a non-binding basis, the Company’s 2025 executive compensation program as disclosed in the proxy statement. Management frames compensation as pay-for-performance, with a high proportion of CEO and NEO compensation variable and at-risk (stock options, RSUs, and performance-based RSUs tied to regulatory milestones), and with annual cash bonuses tied to rigorous research, clinical, regulatory and financial goals. The Compensation Committee emphasizes long-term alignment through stock options and PSUs that vest on BLA-related regulatory milestones, and short-term alignment via performance-based annual bonuses; the Board notes that prior say-on-pay received strong stockholder support (approximately 97.1% in 2025). The vote is advisory and non-binding, but management will consider the outcome when setting future pay policy; the Board recommends a FOR vote citing retention, alignment with stockholder interests, and market-competitive design. For an analyst evaluating governance risk, the program’s heavy reliance on equity and milestone-based PSUs concentrates reward on regulatory success (BLA acceptance and approval) which can create binary outcomes, but also tightly aligns pay to clinical and regulatory milestones central to value creation for a clinical-stage biotech. The company’s disclosure of severance, clawback policy, equity grant practices, and use of an independent compensation consultant (Aon) reduces governance concerns and demonstrates process and oversight. Potential shareholder concerns include dilution from large equity grants, the magnitude of target equity awards (e.g., significant option and PSU awards granted in January 2025), and whether payout metrics adequately capture broader operational performance beyond regulatory events. Overall, the Board’s recommendation, the Company’s prior strong say-on-pay support, and structural features (mix of options/RSUs/PSUs with service and milestone vesting and clawback protections) argue management expects continued backing, but investors should weigh binary milestone exposure and grant magnitudes when judging long-term alignment.

This advisory say-on-frequency proposal asks shareholders to indicate whether future advisory votes on executive compensation should occur every one, two, or three years; the Board recommends an annual (one-year) frequency. Management’s rationale for preferring annual votes is governance responsiveness: more frequent votes allow quicker stockholder feedback on pay programs, faster course correction, and regular evaluation of evolving compensation practices in a clinical-stage biotech where regulatory and clinical developments can rapidly change corporate priorities. The vote is non-binding, but the Board and Compensation Committee will carefully consider the outcome when setting the cadence of future say-on-pay votes. For a governance analyst, an annual frequency favors ongoing engagement and accountability but imposes administrative cost and potential short-termism pressure on compensation design; less frequent votes (two or three years) can reduce administrative burden but limit timely stockholder signals. The Company’s history of holding annual votes and its strong prior say-on-pay support suggest management expects stockholder alignment with an annual cadence, but institutional investors sometimes prefer triennial votes to focus on long-term outcomes. The proxy mechanism provides that if no majority is reached among the three options, the plurality winner will be treated as the preference, which can produce perverse outcomes if votes are split. Overall, the proposal is a governance choice between responsiveness and stability; the Board’s recommendation for annual votes is consistent with its emphasis on active oversight of executive pay and frequent stockholder engagement.

Proposal 5 requests shareholder approval to amend the Certificate of Incorporation to increase authorized common shares from 115 million to 215 million, a management-driven charter amendment designed to provide the company flexibility to support financings, equity incentive grants and at‑the‑market offerings without the delay and expense of repeated stockholder votes. Management’s justification emphasizes that, after accounting for outstanding shares, reserved conversion rights and awards, only about 35,072 shares remained available under the current authorization as of April 3, 2026, which could constrain the company’s ability to execute financing or compensation plans promptly. For analysts, key governance considerations include the magnitude of the increase (an additional 100 million shares, nearly doubling authorization), the potential dilutive effect on existing holders, and the fact that such a large increase can be used for many corporate purposes without additional stockholder approval absent specific triggering rules. The amendment would leave preferred stock unchanged and preserve par value; it will become effective upon filing with the Delaware Secretary of State if approved by the required majority of outstanding shares. The filing includes a proposed Certificate of Amendment (attached as Appendix A) and the Board argues the change is necessary for operational flexibility given recent financings and ongoing clinical/regulatory activities requiring capital. Risk factors include dilution to EPS and voting power, and the potential for perceived entrenchment or defensive use, though the Board disclaims any intent to use the increase to block control transactions; investors should evaluate contemporaneous issuance plans and guardrails (if any) such as preemptive shareholder rights or issuance policies. The voting standard is a majority of outstanding shares entitled to vote, a higher threshold than typical matters, and broker discretionary voting is permitted for this item, which can affect outcomes. Overall, while the amendment provides management with clear operational flexibility to support R&D, clinical/regulatory milestones and capital needs, investors should weigh the dilution risk against the company’s immediate capital needs and disclosed plan to use shares for equity compensation and at‑the‑market financings.

Proposal 6 empowers the Company to adjourn the Annual Meeting if there are insufficient votes to approve Proposal 5, allowing management to continue soliciting proxies and potentially reconvene the meeting at a later date. The proposal is procedural but strategically important because it facilitates the passage of the charter amendment (Proposal 5) by giving management time to solicit additional support; shareholders should view it as enabling rather than substantive. The board states that, if approved, adjournments could be successive and if longer than 30 days notice will be provided to record holders; broker discretionary voting is permitted for this item which may influence outcomes. Governance scrutiny centers on whether adjournment authority could be used to exert pressure on shareholders or to repeatedly solicit votes until a desired result is achieved, though such tactics are common and lawful provided proxy solicitation follows disclosure rules and fiduciary duties. The voting standard is a majority of votes cast, and the Board recommends FOR to preserve the company’s ability to secure the required approval for the charter amendment. For an analyst, this proposal signals management is prioritizing passage of Proposal 5 and planning to use standard procedural mechanisms to achieve it; investors should consider whether they support the underlying charter change before approving an adjournment that could enable additional solicitation.